

Galmed Pharmaceuticals Ltd.  
Form POS EX  
August 04, 2017

**As filed with the Securities and Exchange Commission on August 4, 2017**

Registration No. 333-203133

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Post-Effective Amendment No. 1 to**

**FORM F-3**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**GALMED PHARMACEUTICALS LTD.**

*(Exact name of Registrant as specified in its charter)*

N/A

*(Translation of Registrant's name into English)*

**State of Israel**

**Not Applicable**

*(State or other jurisdiction of incorporation or  
organization)*

*(I.R.S. Employer Identification No.)*

**Galmed Pharmaceuticals Ltd.**

**16 Ze'ev Tiomkin Street**

**Tel Aviv, Israel 6578317**

**Tel: +972.3.693.8448**

*(Address and telephone number of Registrant's principal executive offices)*

**Puglisi & Associates**

**850 Library Avenue, Suite 204**

**Newark, DE 19715**

**(302) 738-6680**

*(Name, address, including zip code, and telephone number, including area code, of agent for service)*

*Copies to:*

**Gary Emmanuel, Esq.**

**McDermott Will & Emery LLP**

**340 Madison Avenue**

**New York, NY 10173**

**(212) 547-5400**

**Approximate date of commencement of proposed sale to the public:** From time to time after the effective date of this Registration Statement.

If only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. "

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. "

If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. "

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. "

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

Emerging growth company  x

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  x

### **Explanatory Note**

Galmed Pharmaceuticals Ltd. (the “Company”) is filing this Post-Effective Amendment No. 1 to the Company’s Registration Statement on Form F-3 (this “Amendment”) pursuant to Rule 462(d) under the Securities Act of 1933, as amended, (the “Securities Act”) solely to file, as Exhibit 99.1, the Signature of the Authorized Representative in the United States, which was inadvertently not included in the original Form F-3 filed with the Securities and Exchange Commission (the “Commission”) on March 31, 2015 (Registration No. 333-203133) (the “Original Form F-3”). This Amendment shall become effective upon filing with the Commission in accordance with Rule 462(d) under the Securities Act.

This Amendment speaks as of the filing date of the Original Form F-3, does not reflect events that have occurred after the filing date of the Original Form F-3, and does not amend, modify or update in any way disclosures made in the Original Form F-3 except as set forth in this explanatory note.

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Signature of the Authorized Representative in the United States

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tel Aviv, State of Israel on this 4th day of August, 2017.

**GALMED PHARMACEUTICALS LTD.**

By: /s/ Allen Baharaff  
 Name: Allen Baharaff  
 Title: President and Chief Executive Officer

In accordance with the requirements of the Securities Act of 1933, this Registration Statement or amendment thereto has been signed by the following persons in the capacities and on the dates indicated:

<b>SIGNATURE</b>	<b>TITLE</b>	<b>DATE</b>
* Chaim Hurvitz	Chairman of the Board, Class III Director; Chairperson of the R&D Committee	August 4, 2017
/s/ Allen Baharaff Allen Baharaff	President and Chief Executive Officer, Class II Director (Principal Executive Officer)	August 4, 2017
/s/ Yohai Stenzler Yohai Stenzler	Chief Financial Officer (Principal Financial and Accounting Officer)	August 4, 2017
* William Marth	Class III Director	August 4, 2017
* Tali Yaron-Eldar	Director; External Director; Chairperson of the Audit Committee; Chairperson of the Remuneration Committee	August 4, 2017
* David Sidransky, M.D.	Director; External Director	August 4, 2017

\* By: /s/ Allen Baharaff,

Allen Baharaff, Attorney-in-Fact